Minnesota Legislature
Office of the Revisor of Statutes
Minnesota Administrative Rules
- Search Minnesota Rules
- About Minnesota Rules
- Agency List
- Table of Chapters
- Rules Index (topics)
- Minnesota Rule Status
- State Register
- Invalid Rules
Chapter 4717
Topics
Part 4717.7860
4717.7860 HEALTH RISK LIMITS TABLE.
§
Subpart 1.
Generally.
This table lists the health risk limits derived from methods specified in parts 4717.7830, 4717.7840, and 4717.7850. For each chemical, this table specifies:
§
Subp. 2.
Explanation of table in this part.
§
E.
The following explanations in subitems (1) to (3) apply where noted:
§
(1)
The acute HRL value is less than the calculated HRL. To be protective of acute exposures, the HRL is set equal to the acute HRL value.
§
(2)
The short-term HRL value is less than the calculated HRL. To be protective of short-term exposures, the HRL is set equal to the short-term HRL value.
§
(3)
The subchronic HRL value is less than the calculated HRL. To be protective of subchronic exposures, the HRL is set equal to the subchronic HRL value.
§
Subp. 2a.
Acenaphthene.
| CAS number: 83-32-9 | |
| Year Adopted: 2018 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 200 | 100 | NA |
| RfD (mg/kg-day) | -- | -- | 0.070 | 0.021 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
| Endpoints | -- | -- | adrenal, hepatic (liver) system | adrenal, hepatic (liver) system | -- |
§
Subp. 2b.
Acetaminophen.
| CAS number: 103-90-2 | |
| Year Adopted: 2015 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 200 | 200 | 200 (2) | 200 (2) | NA |
| RfD (mg/kg-day) | 0.25 | 0.25 | (2) | (2) | -- |
| RSC | 0.2 | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
| Endpoints | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | -- |
§
Subp. 3.
Acetochlor.
| CAS number: 34256-82-1 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 30 | 30 | 20 | NA |
| RfD (mg/kg-day) | -- | 0.016 | 0.012 | 0.0039 | -- |
| RSC | -- | 0.5 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
| Endpoints | -- | developmental, hepatic (liver) system, thyroid (E) | hepatic (liver) system, male reproductive system, nervous system, renal (kidney) system | hepatic (liver) system, male reproductive system, nervous system, renal (kidney) system, respiratory system | -- |
§
Subp. 3a.
Acetochlor ESA.
| CAS number: 187022-11-3 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 500 | 500 | 300 | NA |
| RfD (mg/kg-day) | -- | 0.29 | 0.19 | 0.056 | -- |
| RSC | -- | 0.5 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
| Endpoints | -- | thyroid (E) | male reproductive system, thyroid (E) | male reproductive system, thyroid (E) | -- |
§
Subp. 3b.
Acetochlor OXA.
| CAS number: 184992-44-4 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | 100 (2) | 90 | NA |
| RfD (mg/kg-day) | -- | 0.081 | (2) | 0.019 | -- |
| RSC | -- | 0.5 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | (2) | 0.044 | -- |
| Endpoints | -- | thyroid (E) | thyroid (E) | thyroid (E) | -- |
§
Subp. 3c.
Acetone.
| CAS number: 67-64-1 | |
| Year Adopted: 2023 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 5,000 | 5,000 (2) | 3,000 | NA |
| RfD (mg/kg-day) | -- | 3.1 | (2) | 0.69 | -- |
| RSC | -- | 0.5 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | 0.045 | -- |
| Endpoints | -- | renal (kidney) system | renal (kidney) system | hematological (blood) system, hepatic (liver) system, renal (kidney) system | -- |
§
Subp. 3d.
6-Acetyl-1,1,2,4,4,7-hexamethyltetraline (AHTN).
| CAS number: 21145-77-7 or 1506-02-1 | |
| Year Adopted: 2013 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | 30 | 20 | NA |
| RfD (mg/kg-day) | -- | 0.070 | 0.011 | 0.0037 | -- |
| RSC | -- | 0.5 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | 0.043 | -- |
| Endpoints | -- | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | -- |
§
Subp. 3e.
Acrylamide.
| CAS number: 79-06-1 | |
| Year Adopted: 2015 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 7 | 7 (2) | 7 (2) | 0.2 |
| RfD (mg/kg-day) | -- | 0.010 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.5 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
| Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
| Endpoints | -- | developmental, male reproductive system, nervous system | developmental, male reproductive system, nervous system | developmental, male reproductive system, nervous system | cancer |
§
Subp. 4.
Alachlor.
| CAS number: 15972-60-8 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | 60 | 9 | NA |
| RfD (mg/kg-day) | -- | 0.077 | 0.020 | 0.0020 | -- |
| RSC | -- | 0.5 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
| Endpoints | -- | developmental, renal (kidney) system | hematological (blood) system, hepatic (liver) system, renal (kidney) system | hematological (blood) system, hepatic (liver) system, renal (kidney) system | -- |
§
Subp. 4a.
Aminomethylphosphonic acid (AMPA).
| CAS number: 1066-51-9 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 3,000 | 1,000 | -- |
| RfD (mg/kg-day) | -- | -- | 0.96 | 0.32 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
| Endpoints | -- | -- | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
§
Subp. 5.
Atrazine.
| CAS number: 1912-24-9 | |
| Year Adopted: 2009 | |
| Volatility: Nonvolatile | |
| MCL-based HRL: 3 µg/L |
§
Subp. 5a.
Bentazon.
| CAS number: 25057-89-0 | |
| Year Adopted: 2015 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 400 | 60 | 50 | 30 | NA |
| RfD (mg/kg-day) | 0.22 | 0.033 | 0.020 | 0.0060 | -- |
| RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | 0.077 | 0.043 | -- |
| Endpoints | developmental, female reproductive system | developmental | hematological (blood) system | thyroid | -- |
§
Subp. 6.
Benzene.
| CAS number: 71-43-2 | |
| Year Adopted: 2009 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 10 | 10 | 3 | 3 (3) | 2 |
| RfD (mg/kg-day) | 0.015 | 0.014 | 0.0013 | (3) | -- |
| RSC | 0.2 | 0.2 | 0.2 | (3) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.055 |
| ADAF | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate | 0.289 | 0.289 | 0.077 | (3) | 0.137 (<2) |
| (L/kg-day) | 0.047 (2 to <16) | ||||
| 0.039 (16+) | |||||
| Endpoints | develop- mental |
hemato- logical (blood) system, immune system |
hemato- logical (blood) system, immune system |
hemato- logical (blood) system, immune system |
cancer |
§
Subp. 6c.
Benzo[a]pyrene.
| CAS number: 50-32-8 | |
| Year Adopted: 2023 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 0.5 | 0.5 (2) | 0.5 (2) | 0.1 |
| RfD (mg/kg-day) | -- | 0.00031 | (2) | (2) | -- |
| RSC | -- | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 1 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | 0.155 (<2) |
| 0.040 (2 to <16) | |||||
| 0.042 (16+) | |||||
| Endpoints | -- | developmental, nervous system |
developmental, nervous system |
developmental, nervous system |
cancer |
§
Subp. 6d.
Benzophenone.
| CAS number: 119-61-9 | |
| Year Adopted: 2023 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 900 | 100 | 100 (3) | NA |
| RfD (mg/kg-day) | -- | 0.52 | 0.053 | (3) | -- |
| RSC | -- | 0.5 | 0.2 | (3) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | 0.074 | (3) | -- |
| Endpoints | -- | developmental | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
§
Subp. 6e.
1H-Benzotriazole.
| CAS number: 95-14-7 | |
| Year Adopted: 2023 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 20 | 20 (2) | 20 (2) | NA |
| RfD (mg/kg-day) | -- | 0.023 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | developmental | developmental | developmental | -- |
§
Subp. 6f.
Biphenyl.
| CAS number: 92-52-4 | |
| Year Adopted: 2023 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 400 | 100 | 100 (2) | 100 (2) | 10 |
| RfD (mg/kg-day) | 0.58 | 0.18 | (2) | (2) | -- |
| RSC | 0.2 | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.008 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate (L/kg-day) | 0.290 | 0.290 | (2) | (2) | 0.155 (<2) |
| 0.040 (2 to <16) | |||||
| 0.042 (16+) | |||||
| Endpoints | renal (kidney) system | renal (kidney) system | renal (kidney) system | renal (kidney) system | cancer |
§
Subp. 6g.
Bisphenol A (BPA).
| CAS number: 80-05-7 | |
| Year Adopted: 2015 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | 20 | 20 (3) | NA |
| RfD (mg/kg-day) | -- | 0.16 | 0.0065 | (3) | -- |
| RSC | -- | 0.2 | 0.2 | (3) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | (3) | -- |
| Endpoints | -- | developmental, female reproductive system (E), hepatic (liver) system, male reproductive system (E), renal (kidney) system, thyroid (E) | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
§
Subp. 6h.
Bromodichloromethane.
| CAS number: 75-27-4 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 400 | 30 | 30 (2) | 30 | 3 |
| RfD (mg/kg-day) | 0.073 | 0.039 | (2) | 0.0075 | -- |
| RSC | 0.2 | 0.2 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.035 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate (L/kg-day) | 0.038 | 0.290 | (2) | 0.045 | 0.155 (<2) |
| 0.040 (2 to <16) | |||||
| 0.042 (16+) | |||||
| Endpoints | female reproductive system (E) | immune system, spleen | immune system, spleen | hepatic (liver) system | cancer |
§
Subp. 6i.
Butyl benzyl phthalate.
| CAS number: 85-68-7 | |
| Year Adopted: 2015 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 100 | 100 | 100 (2) | 100 (2) | NA |
| RfD (mg/kg-day) | 0.15 | 0.15 | (2) | (2) | -- |
| RSC | 0.2 | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
| Endpoints | developmental (E) | developmental (E) | developmental (E) | developmental (E) | -- |
§
Subp. 6j.
Cadmium.
| CAS number: 7440-43-9 | |
| Year Adopted: 2015 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 5 | 1 | 1 | 0.5 | NA |
| RfD (mg/kg-day) | 0.0077 | 0.0016 | 0.00044 | 0.00011 | -- |
| RSC | 0.2 | 0.2 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | 0.077 | 0.043 | -- |
| Endpoints | developmental | developmental, nervous system, renal (kidney) system | developmental, skeletal | renal (kidney) system, skeletal | -- |
§
Subp. 6k.
Carbamazepine.
| CAS number: 298-46-4 | |
| Year Adopted: 2013 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 40 | 40 | 40 (2) | 40 (2) | NA |
| RfD (mg/kg-day) | 0.013 | 0.013 | (2) | (2) | -- |
| RSC | 0.8 | 0.8 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate | 0.289 | 0.289 | (2) | (2) | -- |
| (L/kg-day) | |||||
| Endpoints | develop- mental, nervous system |
develop- mental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) |
develop- mental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) |
develop- mental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) |
-- |
§
Subp. 6l.
Carbon tetrachloride.
| CAS number: 56-23-5 | |
| Year Adopted: 2013 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 100 | 3 | 3 (2) | 3 (2) | 1 |
| RfD (mg/kg-day) | 0.18 | 0.0037 | (2) | (2) | -- |
| RSC | 0.2 | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.07 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137 (<2) |
| 0.047 (2 to <16) | |||||
| 0.039 (16+) | |||||
| Endpoints | develop- mental, hepatic (liver) system |
hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | cancer |
§
Subp. 7.
Chloroform.
| CAS number: 67-66-3 | |
| Year Adopted: 2018 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 20 | 20 (2) | 20 (2) | NA |
| RfD (mg/kg-day) | -- | 0.022 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
| Endpoints | -- | developmental, hepatic (liver) system, immune system | developmental, hepatic (liver) system, immune system | developmental, hepatic (liver) system, immune system | -- |
§
Subp. 7a.
Clothianidin.
| CAS number: 210880-92-5, 205510-53-8 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 200 | 200 (2) | 200 (2) | NA |
| RfD (mg/kg-day) | -- | 0.093 | (2) | (2) | -- |
| RSC | -- | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
| Endpoints | -- | developmental | developmental | developmental | -- |
§
Subp. 8.
Cyanazine.
| CAS number: 21725-46-2 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 3 | 3 | 3 | 1 | NA |
| RfD (mg/kg-day) | 0.0015 | 0.0015 | 0.0012 | 0.00022 | -- |
| RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.285 | 0.285 | 0.070 | 0.044 | -- |
| Endpoints | developmental, female reproductive system | developmental, female reproductive system | developmental, female reproductive system, hepatic (liver) system, renal (kidney) system | None | -- |
§
Subp. 8e.
Dibutyl phthalate.
| CAS number: 84-74-2 | |
| Year Adopted: 2015 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 20 | 20 | 20 (2) | 20 (2) | NA |
| RfD (mg/kg-day) | 0.023 | 0.023 | (2) | (2) | -- |
| RSC | 0.2 | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
| Endpoints | developmental (E) | developmental (E) | developmental (E) | developmental (E) | -- |
§
Subp. 8f.
1, 4-Dichlorobenzene.
| CAS number: 106-46-7 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 50 | 50 (2) | 50 (2) | NA |
| RfD (mg/kg-day) | -- | 0.069 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | developmental, hepatic (liver) system, nervous system | developmental, hepatic (liver) system, nervous system | developmental, hepatic (liver) system, nervous system | -- |
§
Subp. 8g.
Dichlorodifluoromethane.
| CAS number: 75-71-8 | |
| Year Adopted: 2011 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | ND | 700 | NA |
| RfD (mg/kg-day) | -- | -- | -- | 0.15 | -- |
| RSC | -- | -- | -- | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | -- | 0.043 | -- |
| Endpoints | -- | -- | -- | None | -- |
§
Subp. 8h.
1,2-Dichloroethane.
| CAS number: 107-06-2 | |
| Year Adopted: 2013 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 200 | 200 (2) | 60 | 1 |
| RfD (mg/kg-day) | -- | 0.23 | (2) | 0.012 | -- |
| RSC | -- | 0.2 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.091 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate (L/kg-day) | -- | 0.289 | (2) | 0.043 | 0.137 (<2) |
| 0.047 (2 to <16) | |||||
| 0.039 (16+) | |||||
| Endpoints | -- | hepatic (liver) system | hepatic (liver) system | renal (kidney) system, hepatic (liver) system | cancer |
§
Subp. 8i.
trans-1,2-Dichloroethene.
| CAS number: 156-60-5 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 50 | 9 | NA |
| RfD (mg/kg-day) | -- | -- | 0.020 | 0.0020 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
| Endpoints | -- | -- | immune system | immune system | -- |
§
Subp. 8j.
1,1-Dichloroethylene (Vinylidene chloride).
| CAS number: 75-35-4 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 200 | 200 | NA |
| RfD (mg/kg-day) | -- | -- | 0.069 | 0.040 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
| Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | -- |
§
Subp. 8k.
1, 2-Dichloropropane.
| CAS number: 78-87-5 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 20 | 20 (2) | 20 (2) | 3 |
| RfD (mg/kg-day) | -- | 0.029 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.037 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | 0.155(<2) 0.040(2 to <16) 0.042 (16+) |
| Endpoints | -- | developmental | developmental | developmental | cancer |
§
Subp. 9.
cis 1,2-Dichloroethylene.
| CAS number: 156-59-2 | |
| Year Adopted: 2018 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 20 | 10 | 6 | NA |
| RfD (mg/kg-day) | -- | 0.033 | 0.0043 | 0.0013 | -- |
| RSC | -- | 0.2 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
| Endpoints | -- | hepatic (liver) system | renal (kidney) system | renal (kidney) system | -- |
§
Subp. 10.
Dichloromethane.
| CAS number: 75-09-2 | |
| Year Adopted: 2009 | |
| Volatility: High | |
| MCL-based HRL: 5 µg/L |
§
Subp. 10a.
2,4-Dichlorophenoxyacetic acid (2,4-D).
| CAS number: 94-75-7 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 30 | 30 (2) | 30 (2) | NA |
| RfD (mg/kg-day) | -- | 0.048 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
| Endpoints | -- | adrenal, developmental, thyroid (E) | adrenal, developmental, thyroid (E) | adrenal, developmental, thyroid (E) | -- |
§
Subp. 11.
Dieldrin.
| CAS number: 60-57-1 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 0.2 | 0.2 (2) | 0.2 | 0.006 |
| RfD (mg/kg-day) | -- | 0.00011 | (2) | 0.000043 | -- |
| RSC | -- | 0.5 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 16 |
| AFlifetime | -- | -- | -- | -- | 2.5 |
| Intake Rate (L/kg-day) | -- | 0.285 | (2) | 0.044 | 0.044 |
| Endpoints | -- | developmental, immune system, nervous system | developmental, immune system, nervous system | developmental, hepatic (liver) system, immune system, nervous system | cancer |
§
Subp. 11c.
Di(2-ethylhexyl) phthalate (DEHP).
| CAS number: 117-81-7 | |
| Year Adopted: 2015 | |
| Volatility: Nonvolatile | |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 20 | 20 | 20 (2) | 20 (2) | 7 |
| RfD (mg/kg-day) | 0.029 | 0.029 | (2) | (2) | -- |
| RSC | 0.2 | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.014 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
| Endpoints | develop- mental (E), male reproductive system (E) |
develop- mental (E), male reproductive system (E) |
develop- mental (E), male reproductive system (E) |
develop- mental (E), male reproductive system (E) |
cancer |
§
Subp. 11d.
N,N-Diethyl-meta-toluamide (DEET).
| CAS number: 134-62-3 | |
| Year Adopted: 2013 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 200 | 200 (2) | 200 (2) | NA |
| RfD (mg/kg-day) | -- | 0.23 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
| Endpoints | -- | developmental, nervous system | developmental, nervous system | developmental, nervous system | -- |
§
Subp. 11e.
Dimethenamid and Dimethenamid-p.
| CAS numbers: 87674-68-8 and 163515-14-8 | |
| Year Adopted: 2015 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 600 | 600 (2) | 300 | NA |
| RfD (mg/kg-day) | -- | 0.34 | (2) | 0.060 | -- |
| RSC | -- | 0.5 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.289 | (2) | 0.043 | -- |
| Endpoints | -- | developmental, female reproductive system, hepatic (liver) system, nervous system | developmental, female reproductive system, hepatic (liver) system, nervous system | hepatic (liver) system | -- |
§
Subp. 11f.
Dinoseb.
| CAS number: 88-85-7 | |
| Year Adopted: 2018 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 8 | 8 (2) | 8 (2) | NA |
| RfD (mg/kg-day) | -- | 0.0048 | (2) | (2) | -- |
| RSC | -- | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
| Endpoints | -- | developmental | developmental | developmental | -- |
§
Subp. 11g.
1,4-Dioxane.
| CAS number: 123-91-1 | |
| Year Adopted: 2013 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 300 | 100 | 1 |
| RfD (mg/kg-day) | -- | -- | 0.12 | 0.025 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.1 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate | -- | -- | 0.077 | 0.043 | 0.137 (<2) |
| (L/kg-day) | 0.047 (2 to <16) | ||||
| 0.039 (16+) | |||||
| Endpoints | -- | -- | hepatic (liver) system, renal (kidney) system, respiratory system | hepatic (liver) system, renal (kidney) system, respiratory system | cancer |
§
Subp. 12a.
17α-Ethinylestradiol.
| CAS number: 57-63-6 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 0.0005 | 0.0002 | 0.0002 | NA |
| RfD (mg/kg-day) | -- | 1.7 x 10-7 | 1.4 x 10-8 | 1.4 x 10-8 | -- |
| RSC | -- | 0.8 | 0.8 | 0.8 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | 0.074 | 0.045 | -- |
| Endpoints | -- | developmental (E), female reproductive system (E), male reproductive system (E) | developmental | developmental | -- |
§
Subp. 12b.
Ethylbenzene.
| CAS number: 100-41-4 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 40 | 40 (2) | 40 (2) | NA |
| RfD (mg/kg-day) | -- | 0.06 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
§
Subp. 12c.
S-Ethyl-N,N-dipropylthiocarbamate (EPTC).
| CAS number: 759-94-4 | |
| Year Adopted: 2018 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 300 | 300 | 90 | 40 | NA |
| RfD (mg/kg-day) | 0.16 | 0.16 | 0.033 | 0.0083 | -- |
| RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.285 | 0.285 | 0.070 | 0.044 | -- |
| Endpoints | nervous system | developmental, female reproductive system, nervous system | cardiovascular system | cardiovascular system | -- |
§
Subp. 12d.
Ethylene glycol.
| CAS number: 107-21-1 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 2,000 | 2,000 | 2,000 | NA |
| RfD (mg/kg-day) | -- | 0.33 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.038 | (2) | (2) | -- |
| Endpoints | -- | developmental | developmental, renal (kidney) system | developmental, male reproductive system, renal (kidney) system | -- |
§
Subp. 12e.
Fluoranthene.
| CAS number: 206-44-0 | |
| Year Adopted: 2018 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 200 | 70 | NA |
| RfD (mg/kg-day) | -- | -- | 0.053 | 0.016 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
| Endpoints | -- | -- | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
§
Subp. 12f.
Fluorene (9H-Fluorene).
| CAS number: 86-73-7 | |
| Year Adopted: 2023 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 200 | 80 | NA |
| RfD (mg/kg-day) | -- | -- | 0.058 | 0.018 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
| Endpoints | -- | -- | hematological (blood) system, spleen | hematological (blood) system, spleen | -- |
§
Subp. 12g.
Fomesafen.
| CAS number: 72178-02-0 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 200 | 200 (2) | 20 | NA |
| RfD (mg/kg-day) | -- | 0.12 | (2) | 0.005 | -- |
| RSC | -- | 0.5 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | 0.045 | -- |
| Endpoints | -- | developmental, hepatic (liver) system, immune system | developmental, hepatic (liver) system, immune system | hepatic (liver) system | -- |
§
Subp. 12h.
Imidacloprid.
| CAS number: 138261-41-3 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 100 | 2 | 2 (2) | 2 (2) | NA |
| RfD (mg/kg-day) | 0.15 | 0.0036 | (2) | (2) | -- |
| RSC | 0.2 | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.290 | 0.290 | (2) | (2) | -- |
| Endpoints | nervous system | immune system | immune system | immune system | -- |
§
Subp. 12i.
Manganese.
| CAS number: 7439-96-5 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | ND | ND | NA |
| RfD (mg/kg-day) | -- | 0.083 | -- | -- | -- |
| RSC | -- | 0.5 | -- | -- | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | -- | -- | -- |
| Endpoints | -- | developmental, nervous system | -- | -- | -- |
§
Subp. 12j.
Metolachlor and S-Metolachlor.
| CAS number: 51218-45-2; 87392-12-9 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 300 | 300 (2) | 300 (2) | NA |
| RfD (mg/kg-day) | -- | 0.19 | (2) | (2) | -- |
| RSC | -- | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | developmental | developmental | developmental | -- |
§
Subp. 12k.
Metolachlor ESA.
| CAS number: 171118-09-5 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 7,000 | 1,000 | NA |
| RfD (mg/kg-day) | -- | -- | 2.7 | 0.27 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | -- |
| Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | -- |
§
Subp. 12l.
Metolachlor OXA.
| CAS number: 152019-73-3 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 5,000 | 5,000 (2) | 1,000 | NA |
| RfD (mg/kg-day) | -- | 2.7 | (2) | 0.27 | -- |
| RSC | -- | 0.5 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | 0.045 | -- |
| Endpoints | -- | none | none | none | -- |
§
Subp. 12m.
Metribuzin.
| CAS number: 21087-64-9 | |
| Year Adopted: 2013 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 30 | 10 | 10 (2) | 10 (2) | NA |
| RfD (mg/kg-day) | 0.016 | 0.006 | (2) | (2) | -- |
| RSC | 0.5 | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
| Endpoints | developmental, nervous system | thyroid (E) | thyroid (E) | thyroid (E) | -- |
§
Subp. 12n.
Naphthalene.
| CAS number: 91-20-3 | |
| Year Adopted: 2013 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 70 | 70 | 70 (2) | 70 | NA |
| RfD (mg/kg-day) | 0.038 | 0.038 | (2) | 0.016 | -- |
| RSC | 0.5 | 0.5 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | 0.043 | -- |
| Endpoints | nervous system | nervous system | nervous system | nervous system, spleen | -- |
§
Subp. 13.
Nitrate (as N).
| CAS number: 14797-55-8 | |
| Year Adopted: 2009 | |
| Volatility: Nonvolatile | |
| MCL-based HRL: 10,000 µg/L |
§
Subp. 13a.
p-Nonylphenol (4-Nonylphenol).
| CAS number: 84852-15-3 | |
| Year Adopted: 2023 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | 40 | 20 | NA |
| RfD (mg/kg-day) | -- | 0.21 | 0.016 | 0.0049 | -- |
| RSC | -- | 0.2 | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | 0.074 | 0.045 | -- |
| Endpoints | -- | developmental, female reproductive system | renal (kidney) system | renal (kidney) system | -- |
§
Subp. 13b.
4-tert-Octylphenol.
| CAS number: 140-66-9 | |
| Year Adopted: 2023 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | 100 (2) | 100 (2) | NA |
| RfD (mg/kg-day) | -- | 0.17 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | developmental | developmental | developmental | -- |
§
Subp. 14.
Pentachlorophenol (PCP).
| CAS number: 87-86-5 | |
| Year Adopted: 2015 | |
| Volatility: Low | |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 7 | 7 | 7 (2) | 7 (2) | 0.3 |
| RfD (mg/kg-day) | 0.0040 | 0.0040 | (2) | (2) | -- |
| RSC | 0.5 | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.4 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
| Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
| Endpoints | develop- mental, thyroid (E) |
develop- mental (E), thyroid (E) |
develop- mental (E), hepatic (liver) system, immune system, male reproductive system, thyroid (E) |
develop- mental (E), hepatic (liver) system, immune system, male reproductive system, thyroid (E) |
cancer |
§
Subp. 14a.
Perfluorobutane sulfonate (PFBS).
| CAS number: 45187-15-3; 375-73-5; 29420-49-3; 68259-10-9; 60453-92-1 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 0.1 | 0.1 (2) | 0.1 (2) | NA |
| RfD (mg/kg-day) | -- | 0.000084 | (2) | (2) | -- |
| RSC | -- | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | thyroid (E) | thyroid (E) | thyroid (E) | -- |
§
Subp. 14b.
Perfluorobutanoate (PFBA).
| CAS number: 45048-62-2; 375-22-4 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 7 | 7 (2) | 7 (2) | NA |
| RfD (mg/kg-day) | -- | 0.0038 | (2) | (2) | -- |
| RSC | -- | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
| Endpoints | -- | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | -- |
§
Subp. 14c.
Perfluorohexane sulfonate (PFHxS) and salts.
| CAS number: 108427-53-8; 355-46-4; 3871-99-6 | |
| Year Adopted: 2023 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | NA | 0.047 | 0.047 | 0.047 | NA |
| RfD (mg/kg-day) | -- | 0.0000097 | 0.0000097 | 0.0000097 | -- |
| RSC | -- | 0.5 | -- | -- | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | * | * | * | -- |
| Endpoints | -- | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | -- |
* 95th percentile water intake rates (Tables 3-1, 3-3, and 3-5 Environmental Protection Agency, Exposure Factors Handbook, 2019) or upper percentile breast milk intake rates (Table 15-1, Environmental Protection Agency, Exposure Factors Handbook, 2011), and MDH background information.
§
Subp. 14d.
Perfluorohexanoate (PFHxA) and salts.
| CAS number: 92912-52-7; 307-24-4; 21615-47-4; 2923-26-4 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 0.2 | 0.2 (2) | 0.2 (2) | NA |
| RfD (mg/kg-day) | -- | 0.00032 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | developmental, thyroid (E) | developmental, thyroid (E) | developmental, thyroid (E) | -- |
§
Subp. 15.
Perfluorooctane sulfonate (PFOS) and salts.
| CAS number: 45298-90-6; 1763-23-1; 29081-56-9; 2795-39-3; 70225-14-8; and 29457-72-5 | |
| Year Adopted: 2009 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | ND | 0.3 | NA |
| RfD (mg/kg-day) | -- | -- | -- | 0.00008 | -- |
| RSC | -- | -- | -- | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | -- | 0.049 | -- |
| Endpoints | -- | -- | -- | developmental, hepatic (liver) system, thyroid (E) |
-- |
§
Subp. 16.
Perfluorooctanoate (PFOA) and salts.
| CAS number: 45285-51-6; 335-67-1; 335-66-0; 3825-26-1; 2395-00-8; 335-93-3; and 335-95-5 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 0.035 | 0.035 | 0.035 | NA |
| RfD (mg/kg-day) | -- | 0.000018 | 0.000018 | 0.000018 | -- |
| RSC | -- | 0.5 | 0.5 | 0.5 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | * | * | * | -- |
| Endpoints | -- | developmental, hepatic (liver) system, immune system, renal (kidney) system | developmental, hepatic (liver) system, immune system, renal (kidney) system | developmental, hepatic (liver) system, immune system, renal (kidney) system | -- |
* 95th percentile water intake rates (Tables 3-1 and 3-3), or upper percentile breast milk intake rates (Table 15-1), Environmental Protection Agency (EPA) Exposure Factors Handbook, 2011.
§
Subp. 16a.
Pyrene.
| CAS number: 129-00-0 | |
| Year Adopted: 2018 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 90 | 50 | NA |
| RfD (mg/kg-day) | -- | -- | 0.033 | 0.010 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
| Endpoints | -- | -- | renal (kidney) system | renal (kidney) system | -- |
§
Subp. 16b.
Quinoline.
| CAS number: 91-22-5 | |
| Year Adopted: 2023 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | ND | 4 | 0.03 |
| RfD (mg/kg-day) | -- | -- | -- | 0.00079 | -- |
| RSC | -- | -- | -- | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 3 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate | -- | -- | -- | 0.045 | 0.155 (<2) |
| (L/kg-day) | 0.040 (2 to <16) | ||||
| 0.042 (16+) | |||||
| Endpoints | -- | -- | -- | hematological (blood) system, hepatic (liver) system, renal (kidney) system, respiratory system, and spleen | cancer |
§
Subp. 17.
Simazine.
| CAS number: 122-34-9 | |
| Year Adopted: 2009 | |
| Volatility: Nonvolatile | |
| MCL-based HRL: 4 µg/L |
§
Subp. 17a.
Sulfamethazine (includes sodium salt form).
| CAS number: 57-68-1 (1981-58-4) | |
| Year Adopted: 2015 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | 100 (2) | 100 (2) | NA |
| RfD (mg/kg-day) | -- | 0.040 | (2) | (2) | -- |
| RSC | -- | 0.8 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
| Endpoints | -- | thyroid | thyroid | thyroid | -- |
§
Subp. 18.
Tetrachloroethylene (PCE or PERC).
| CAS number: 127-18-4 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 7 | 7 (3) | 4 |
| RfD (mg/kg-day) | -- | -- | 0.0026 | (3) | -- |
| RSC | -- | -- | 0.2 | (3) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.0249 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
| Intake Rate (L/kg-day) | -- | -- | 0.074 | (3) | 0.155(<2) 0.040(2 to <16) 0.042 (16+) |
| Endpoints | -- | -- | nervous system | nervous system | cancer |
§
Subp. 18a.
Tetrahydrofuran.
| CAS number: 109-99-9 | |
| Year Adopted: 2018 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 600 | 600 (2) | 600 (2) | NA |
| RfD (mg/kg-day) | -- | 0.82 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
| Endpoints | -- | developmental | developmental | developmental | -- |
§
Subp. 18b.
Thiamethoxam.
| CAS number: 153719-23-4 | |
| Year Adopted: 2018 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 400 | 200 | 200 (3) | NA |
| RfD (mg/kg-day) | -- | 0.25 | 0.057 | (3) | -- |
| RSC | -- | 0.5 | 0.2 | (3) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | (3) | -- |
| Endpoints | -- | developmental, female reproductive system, hepatic (liver) system | male reproductive system | male reproductive system | -- |
§
Subp. 18c.
Toluene.
| CAS number: 108-88-3 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 70 | 70 (2) | 70 (2) | NA |
| RfD (mg/kg-day) | -- | 0.10 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | immune system, nervous system | immune system, nervous system | immune system, nervous system | -- |
§
Subp. 18d.
1,2,4-Trichlorobenezene.
| CAS number: 120-82-1 | |
| Year Adopted: 2013 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 100 | 100 (2) | 100 | 4 |
| RfD (mg/kg-day) | -- | 0.17 | (2) | 0.021 | -- |
| RSC | -- | 0.2 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.029 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate | -- | 0.289 | (2) | 0.043 | 0.137 (<2) |
| (L/kg-day) | 0.047 (2 to <16) | ||||
| 0.039 (16+) | |||||
| Endpoints | -- | hepatic (liver) system, adrenal (E), hemato- logical (blood) system |
hepatic (liver) system, adrenal (E), hemato- logical (blood) system |
hepatic (liver) system, adrenal (E), renal (kidney) system | cancer |
§
Subp. 19.
1,1,1-Trichloroethane.
| CAS number: 71-55-6 | |
| Year Adopted: 2018 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 9,000 | 5,000 | NA |
| RfD (mg/kg-day) | -- | -- | 3.0 | 1.0 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
| Endpoints | -- | -- | hepatic (liver) system, male reproductive system | hepatic (liver) system, male reproductive system | -- |
§
Subp. 20.
1,1,2-Trichloroethylene (TCE).
| CAS number: 79-01-6 | |
| Year Adopted: 2015 | |
| Volatility: High | |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 0.4 | 0.4 | 0.4 (3) | 2 |
| RfD (mg/kg-day) | -- | 0.00052 | 0.00017 | (3) | -- |
| RSC | -- | 0.2 | 0.2 | (3) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.05 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
| Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | (3) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
| Endpoints | -- | develop- mental, immune system |
develop- mental, immune system |
develop- mental, immune system |
cancer |
§
Subp. 21.
2(2,4,5-Trichlorophenoxy)propionic acid (2,4,5-TP or Silvex).
| CAS number: 93-72-1 | |
| Year Adopted: 2009 | |
| Volatility: Nonvolatile | |
| MCL-based HRL: 50 µg/L |
§
Subp. 21a.
1,2,3-Trichloropropane.
| CAS number: 96-18-4 | |
| Year Adopted: 2013 | |
| Volatility: Moderate |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 7 | 7 | 7 (2) | 7 (2) | 0.003 |
| RfD (mg/kg-day) | 0.0042 | 0.0042 | (2) | (2) | -- |
| RSC | 0.5 | 0.5 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 30 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate | 0.289 | 0.289 | (2) | (2) | 0.137 (<2) |
| (L/kg-day) | 0.047 (2 to <16) | ||||
| 0.039 (16+) | |||||
| Endpoints | develop- mental |
develop- mental |
develop- mental |
develop- mental |
cancer |
§
Subp. 21b.
1,2,3-Trimethylbenzene.
| CAS number: 526-73-8 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 30 | 30 (2) | 30 (2) | NA |
| RfD (mg/kg-day) | -- | 0.042 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | nervous system | nervous system | nervous system | -- |
§
Subp. 21c.
1,2,4-Trimethylbenzene.
| CAS number: 95-63-6 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 30 | 30 (2) | 30 (2) | NA |
| RfD (mg/kg-day) | -- | 0.042 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | nervous system | nervous system | nervous system | -- |
§
Subp. 22.
1,3,5-Trimethylbenzene.
| CAS number: 108-67-8 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 30 | 30 (2) | 30 (2) | NA |
| RfD (mg/kg-day) | -- | 0.042 | (2) | (2) | -- |
| RSC | -- | 0.2 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | nervous system | nervous system | nervous system | -- |
§
Subp. 22a.
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)
| CAS number: 13674-87-8 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 20 | 8 | 0.8 |
| RfD (mg/kg-day) | -- | -- | 0.0067 | 0.0019 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.13 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
| Intake Rate (L/kg-day) | -- | -- | 0.074 | 0.045 | 0.155(<2) 0.040(2 to <16) 0.042 (16+) |
| Endpoints | -- | -- | hepatic (liver) system; kidney system | male reproductive system; renal (kidney) system | cancer |
§
Subp. 22b.
Tris(2-butoxyethyl) phosphate (TBEP)
| CAS number: 78-51-3 | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 30 | 30 (2) | 30 | NA |
| RfD (mg/kg-day) | -- | 0.043 | (2) | 0.0074 | -- |
| RSC | -- | 0.2 | (2) | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | 0.045 | -- |
| Endpoints | -- | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | -- |
§
Subp. 22c.
Tris(2-chloroethyl) phosphate.
| CAS number: 115-96-8 | |
| Year Adopted: 2013 | |
| Volatility: Low |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 300 | 200 | 200 (3) | 5 |
| RfD (mg/kg-day) | -- | 0.15 | 0.068 | (3) | -- |
| RSC | -- | 0.5 | 0.2 | (3) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 0.02 |
| ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
| 3 (ADAF2 to <16) | |||||
| 1 (ADAF16+) | |||||
| Intake Rate | -- | 0.289 | 0.077 | (3) | 0.137 (<2) |
| (L/kg-day) | 0.047 (2 to <16) | ||||
| 0.039 (16+) | |||||
| Endpoints | -- | renal (kidney) system, nervous system, develop- mental |
renal (kidney) system | renal (kidney) system | cancer |
§
Subp. 22d.
Venlafaxine.
| CAS number: 93413-69-5 (free base), 93300-78-4 (HCl salt) | |
| Year Adopted: 2023 | |
| Volatility: Nonvolatile |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | 10 | 10 (2) | 10 (2) | NA |
| RfD (mg/kg-day) | -- | 0.0054 | (2) | (2) | -- |
| RSC | -- | 0.8 | (2) | (2) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | -- | 0.290 | (2) | (2) | -- |
| Endpoints | -- | developmental, gastrointestinal system, male reproductive system, nervous system (E) | developmental, gastrointestinal system, male reproductive system, nervous system (E) | developmental, gastrointestinal system, male reproductive system, nervous system (E) | -- |
§
Subp. 23.
Vinyl Chloride.
| CAS number: 75-01-4 | |
| Year Adopted: 2018 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | ND | ND | 90 | 10 | 0.2 |
| RfD (mg/kg-day) | -- | -- | 0.033 | 0.0030 | -- |
| RSC | -- | -- | 0.2 | 0.2 | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | 1.4 |
| AFlifetime | -- | -- | -- | -- | 1 |
| Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | 0.044 |
| Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | cancer |
§
Subp. 23a.
Xylenes.
| CAS number: 1330-20-7 | |
| Year Adopted: 2023 | |
| Volatility: High |
| Acute | Short-term | Subchronic | Chronic | Cancer | |
| HRL (µg/L) | 700 | 300 | 300 | 300 (3) | NA |
| RfD (mg/kg-day) | 1.0 | 0.38 | 0.12 | (3) | -- |
| RSC | 0.2 | 0.2 | 0.2 | (3) | -- |
| SF (per mg/kg-day) | -- | -- | -- | -- | -- |
| ADAF or AFlifetime | -- | -- | -- | -- | -- |
| Intake Rate (L/kg-day) | 0.290 | 0.290 | 0.074 | (3) | -- |
| Endpoints | nervous system | developmental, nervous system | developmental, renal (kidney) system, nervous system | developmental, renal (kidney) system, nervous system | -- |
History:
33 SR 1792; 35 SR 1395; 38 SR 397; 40 SR 689; 43 SR 262; 48 SR 465
Published Electronically:
November 22, 2023
Official Publication of the State of Minnesota
Revisor of Statutes